PopVax has raised more than $33.5 million through a combination of research grants and private investments. The company received around $26.5 million in grants and over $7.5 million in equity funding. Major supporters include the Bill & Melinda Gates Foundation, Vitalik Buterin’s Balvi fund, BARDA (US Biomedical Advanced Research and Development Authority), and Good Ventures, led by Dustin Moskovitz and Cari Tuna.
The company is not simply developing another vaccine. PopVax is combining machine learning, computational protein design, and automated laboratory systems to create open-source, broadly protective mRNA vaccine technologies. Unlike traditional mRNA vaccines that require extremely cold storage conditions, PopVax is building thermostable formulations using advanced lipid-polymer delivery systems and specialized ionizable lipids. This innovation allows vaccines to remain stable in normal refrigeration environments, making large-scale distribution much easier, especially in developing countries.
The project is important because it aims to remove infrastructure barriers and reduce dependence on centralized biotech supply chains. Through its RNA Foundry research hub, PopVax uses decentralized global talent and lower-cost research methods to rapidly test new vaccine designs. By adopting an open-source approach, the company hopes to create a fast-response system capable of protecting populations against seasonal flu, future pandemics, and emerging infectious diseases worldwide.
